Inactive Instrument

2cureX AB (publ) Stock price Nasdaq Stockholm

Equities

SE0010468124

Biotechnology & Medical Research

Sales 2021 7.39M 690K Sales 2022 3.37M 315K Capitalization 143M 13.4M
Net income 2021 -18M -1.68M Net income 2022 -29M -2.71M EV / Sales 2021 29.9 x
Net cash position 2021 72.94M 6.81M Net cash position 2022 44.89M 4.19M EV / Sales 2022 29.3 x
P/E ratio 2021
-14.6 x
P/E ratio 2022
-4.81 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 42.42%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on 2cureX AB (publ)

Managers TitleAgeSince
Chief Executive Officer 48 21-01-31
Founder 65 05-12-31
Founder 71 05-12-31
Members of the board TitleAgeSince
Founder 71 05-12-31
Chairman - Nov. 13
More insiders
2cureX AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of diagnostic substances to select treatment for cancer patients. The Company's product candidate, IndiTreat - CRC, aims at optimizing medical treatment for the colorectal cancer patients. Through IndiTreat - CRC, healthcare professionals collect a tumor sample from patients to create a number of three-dimensional micro tumors in order to test available chemotherapies and experimental treatments. The Company's product pipeline includes also IndiTreat - OVA, targeting ovarian cancer treatment, and IndiTreat - KDN, focusing on kidney cancer treatment. It operates through 2cureX A/S.
More about the company
  1. Stock
  2. Equities
  3. Stock 2cureX AB
  4. Stock 2cureX AB (publ) - Nasdaq Stockholm